Sigyn Therapeutics, Inc. is exploring strategic options including potential mergers and asset sales as the company navigates challenges related to its Nasdaq listing aspirations. The company's CEO Jim Joyce detailed these initiatives in a shareholder update, highlighting how exchange listing issues have impacted the company's ability to fund operations without harming shareholder value. The company's lead therapeutic candidate, CardioDialysis™, represents a significant opportunity in healthcare by targeting cholesterol-transporting lipoproteins and inflammatory molecules using existing dialysis infrastructure.
According to Joyce, lipoprotein apheresis devices that reduce cholesterol-transporting lipoproteins demonstrate greater reduction in major adverse cardiovascular events than pharmaceutical interventions, but are limited to fewer than 60 specialized centers in the United States. CardioDialysis™ is designed for use on dialysis machines already located at more than 7,500 dialysis clinics nationwide, potentially expanding access to this treatment approach. Beyond cardiovascular applications, CardioDialysis™ also shows promise for sepsis treatment, a condition currently lacking approved therapies. The device has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators from human blood plasma.
Joyce noted that industry colleagues at Spectral Medical, a company with approximately $300 million market value, are advancing the PMX hemoadsorption device through clinical studies for sepsis treatment. Should the PMX device receive FDA clearance, CardioDialysis™'s broader mechanism of action could position it as a competitive alternative. The company's strategic challenges stem from its failed attempt to uplist from the OTCQB market to Nasdaq. Joyce explained that the financing for the uplist was a firm commitment offering led by a FINRA member broker-dealer, supported by the same team that successfully executed his previous company's Nasdaq listing.
However, regulatory complications emerged when Nasdaq requested to review and approve investors before the SEC deemed the registration statement effective, creating what Joyce described as a "catch-22" situation. The company eventually withdrew the registration statement underlying the uplist financing. To address these challenges, Sigyn is considering several strategies outlined in a previous shareholder update available at https://www.sigyntherapeutics.com/investors/news-events/press-releases/detail/118/sigyn-therapeutics-issues-shareholder-update-highlighting. These include the sale of certain assets and a potential merger with a Nasdaq-listed company facing compliance issues with forthcoming listing requirements.
Joyce emphasized that while share price and exchange listing don't affect the therapeutic potential of Sigyn's technologies, they significantly impact the company's ability to raise capital without diluting shareholder value. The company's development pipeline extends beyond CardioDialysis™ to include ImmunePrep™ for optimizing immunotherapeutic antibody delivery in cancer treatment, ChemoPrep™ for enhancing targeted chemotherapy delivery, and ChemoPure™ for reducing chemotherapy toxicity. These technologies aim to improve and extend patient lives while offering strategic value to the dialysis and biopharmaceutical industries. As of March 11, 2026, Sigyn Therapeutics reported 2,330,042 shares outstanding, with the company continuing to advance its therapeutic candidates despite current financial and strategic challenges.
